Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias

NCT07895017 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07895017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
Lead sponsor
University of Virginia
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
August 31, 2029
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 1 arm.

  • Avatrombopag Arm ExperimentalAvatrombopag

    All participants are anticipated to receive a 39 day supply of oral Avatrombopag.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Number of participants with platelets ≥50K From enrollment to Day 35

    Number of participants with platelets ≥50K for 2 consecutive laboratory checks within 1 week, and one of those measures occurring at day 28. The last platelet transfusion must be \>2 days from the first day of platelets ≥50K.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Avatrombopag 1 Orange Book patentPatent cliff July 28, 2027 (Orange Book patent)
    • US 7638536; expires July 28, 2027; assignee Astellas Pharma (Japan)

Lead sponsor's other trials

University of Virginia, most recent start first.

Similar trials

Same condition (Thrombocytopenia) and phase, most recent start first.